Other limitations include non-standardized cutoff to access PD-L1 positivity, unreliable predictive ability in CRC and HCC [235], different detection techniques [236], and the types of cells expressing PD-1/PD-L1 molecule within the tumor [237]. This evidence concerns the gene RPL17 and neoplasm.